A BCC Skin Sancer, is the most common cancer. It rarely metastasizes or kills. However, because it can cause significant destruction and disfigurement by invading surrounding tissues, it is still considered malignant.
Pictures of BCC's treated with Curaderm-BEC5:
This patient has a BCC over her left eye. Careful application of Curaderm was required to ensure that the cream did not enter her eye. During the treatment the distinct tumor was surrounded by some inflammation due to the delicacy of the area. The total treatment period was only 9 weeks and clinical assessment 5 years post treatment revealed that there was no recurrence.
This clinically diagnosed BCC appears to be two distinct lesions however; during treatment with Curaderm it becomes apparent that it is in fact one large BCC (3cm x 4cm). After treatment the lesion is completely ablates and some scar tissue can be seen. The treatment period for this case was 16 weeks. Clinical assessment 5 years post treatment revealed that there was no recurrence.
This patient has a BCC on the arm. It is notable how small the lesion appeared before Curaderm therapy. During therapy it was clear that Curaderm was attacking and killing all of the cancerous cells. The extent of the cancerous cells of the lesion was not apparent before treatment with Curaderm thus; Curaderm exposes the clinically unnoticed cancer cells and eliminates them. The treatment period was 8 weeks. Clinical assessment five years post treatment revealed that there was no recurrence
A study lead by Cédric Blanpain, MD / PhD, Professor at Université libre de Bruxelles (ULB), and published in the advanced online publication of Nature Cell Biology, shows new findings about the origin of basal cell carcinoma.